Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Frontline DLBCL Treatment Approaches

MyCancerHaven

R. Vij, H. Cherng

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Optimizing 2L DLBCL Treatment Strategies for CAR-T Ineligible Patien…

Sarah Rutherford